for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Becton Dickinson and Co

BDX.N

Latest Trade

241.53USD

Change

2.26(+0.94%)

Volume

446,334

Today's Range

238.83

 - 

242.94

52 Week Range

197.75

 - 

286.67

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
239.27
Open
239.04
Volume
446,334
3M AVG Volume
45.64
Today's High
242.94
Today's Low
238.83
52 Week High
286.67
52 Week Low
197.75
Shares Out (MIL)
289.78
Market Cap (MIL)
69,335.77
Forward P/E
22.44
Dividend (Yield %)
1.32

Next Event

Q3 2020 Becton Dickinson and Co Earnings Release

Latest Developments

More

BD Prices Offerings Of $1.5 Bln Of Common Stock And $1.5 Bln Of Depositary Shares

Becton Dickinson Withdraws Fiscal Year 2020 Guidance Due To Covid-19

Becton Dickinson And Co - Provides Update On Two Previously Announced Voluntary Recalls Related To Ambulatory Infusion Pumps And Sets

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Becton Dickinson and Co

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.

Industry

Medical Equipment & Supplies

Contact Info

1 Becton Dr

FRANKLIN LAKES, NJ

07417-1815

United States

+1.201.8476800

http://www.bd.com/

Executive Leadership

Vincent A. Forlenza

Executive Chairman of the Board

Thomas E. Polen

President, Chief Executive Officer, Chief Operating Officer, Director

Christopher R. Reidy

Chief Financial Officer, Executive Vice President, Chief Administrative Officer

Betty D. Larson

Executive Vice President- Human Resources, Chief Human Resources

Samrat S. Khichi

Executive Vice President, General Counsel

Key Stats

2.11 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

12.1K

2018

16.0K

2019

17.3K

2020(E)

16.9K
EPS (USD)

2017

9.480

2018

11.010

2019

11.680

2020(E)

10.413
Price To Earnings (TTM)
77.09
Price To Sales (TTM)
3.98
Price To Book (MRQ)
3.10
Price To Cash Flow (TTM)
22.77
Total Debt To Equity (MRQ)
101.03
LT Debt To Equity (MRQ)
80.23
Return on Investment (TTM)
2.22
Return on Equity (TTM)
1.89

Latest News

Latest News

BRIEF-BD Prices Offerings Of $1.5 Bln Of Common Stock And $1.5 Bln Of Depositary Shares

* BD PRICES OFFERINGS OF $1.5 BILLION OF COMMON STOCK AND $1.5 BILLION OF DEPOSITARY SHARES REPRESENTING INTERESTS IN MANDATORY CONVERTIBLE PREFERRED STOCK

BRIEF-Becton Dickinson Issued $750 Mln Of 2.823% Notes Due May 20, 2030 On May 20

* BECTON DICKINSON -ON MAY 20, ISSUED $750 MILLION OF 2.823% NOTES DUE MAY 20, 2030 AND $750 MILLION OF 3.794% NOTES DUE MAY 20, 2050 Source text: (https://bit.ly/2Zu27lU) Further company coverage:

BRIEF-BD Announces Offerings Of $1.5 Bln Of Common Stock And $1.5 Bln Of Depositary Shares

* BD ANNOUNCES OFFERINGS OF $1.5 BILLION OF COMMON STOCK AND $1.5 BILLION OF DEPOSITARY SHARES REPRESENTING INTERESTS IN MANDATORY CONVERTIBLE PREFERRED STOCK

BRIEF-Becton Dickinson Files Prospectus Supplement Related To A Potential Two-Part Notes Offering - SEC Filing

* BECTON DICKINSON AND CO FILES PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL TWO-PART NOTES OFFERING - SEC FILING Source : (https://bit.ly/2WnyKjx) Further company coverage:

Becton Dickinson to boost testing capacity for potential second COVID-19 wave

Medical technology company Becton Dickinson and Co said on Thursday it was preparing to ramp up manufacturing operations to handle demand for COVID-19 testing kits in the event of a second wave of infections in the fall.

BRIEF-Becton Dickinson Withdraws Fiscal Year 2020 Guidance Due To Covid-19

* BD ANNOUNCES RESULTS FOR 2020 SECOND FISCAL QUARTER; WITHDRAWS FISCAL YEAR 2020 GUIDANCE DUE TO COVID-19 PANDEMIC

BRIEF-Becton Dickinson And Co - Provides Update On Two Previously Announced Voluntary Recalls Related To Ambulatory Infusion Pumps And Sets

* BECTON DICKINSON AND CO - PROVIDES UPDATE ON TWO PREVIOUSLY ANNOUNCED VOLUNTARY RECALLS RELATED TO AMBULATORY INFUSION PUMPS AND SETS

BRIEF-Becton Dickinson Announces Second FDA EUA, CE Mark For New Covid-19 Test

* BD ANNOUNCES SECOND FDA EMERGENCY USE AUTHORIZATION, CE MARK FOR NEW COVID-19 MOLECULAR DIAGNOSTIC FOR GLOBAL USE

BRIEF-Becton Dickinson Entered Into Amendment To Term Loan Agreement

* BECTON DICKINSON AND CO - ON MARCH 27 ENTERED INTO AMENDMENT TO TERM LOAN AGREEMENT - SEC FILING

Becton Dickinson, BioMedomics launch test to detect past, current coronavirus exposure

(This March 31 story corrects to remove reference to companies needing to apply for regulatory clearance; clarifies FDA guidance in 6th paragraph.)

Becton Dickinson, BioMedomics launch test to detect past, current coronavirus exposure

Becton Dickinson and Co and diagnostics company BioMedomics on Tuesday said they will launch a diagnostic test that can detect current or past exposure to the coronavirus within minutes, and can be used in doctors' offices, as well as other settings.

BRIEF-BD, BioMedomics Announce Launch Of Rapid Serology Test To Detect Exposure To COVID-19

* BD, BIOMEDOMICS ANNOUNCE LAUNCH OF RAPID SEROLOGY TEST TO DETECT EXPOSURE TO COVID-19 Source text for Eikon: Further company coverage:

BRIEF-On March 20, Becton Dickinson Entered Into A 364-Day Term Loan Agreement

* BECTON DICKINSON AND CO - ON MARCH 20, CO ENTERED INTO A 364-DAY TERM LOAN AGREEMENT

BRIEF-FDA Says Becton Dickinson Carefusion 303 Recalls Alaris System Infusion Pumps Due To Software, System Errors

* FDA- BECTON DICKINSON CAREFUSION 303 RECALLS ALARIS SYSTEM INFUSION PUMPS DUE TO SOFTWARE AND SYSTEM ERRORS

BRIEF-Bd, Babson Diagnostics Announce Strategic Partnership Agreement To Enable Small-Volume Blood Collection For Diagnostic Testing In Retail Settings

* BD, BABSON DIAGNOSTICS ANNOUNCE STRATEGIC PARTNERSHIP AGREEMENT TO ENABLE SMALL-VOLUME BLOOD COLLECTION FOR DIAGNOSTIC TESTING IN RETAIL SETTINGS

Becton Dickinson heads for worst day in over 20 years on full-year forecast cut

Becton Dickinson and Co's <BDX.N> shares plummeted 10%, the biggest one-day drop in over 20 years, after the medical device maker cut its 2020 forecast expecting a hit from the recall of its Alaris pumps used for infusing drugs into patients' body.

U.S. investigates bloodstream infections for link to heparin syringes

Health agencies are investigating an outbreak of bloodstream infections in children from four U.S. states that may be linked to heparin and saline syringes made by Becton Dickinson and Co, the agencies told Reuters. The U.S. Centers for Disease Control and Prevention has...

BRIEF-Becton Dickinson Reports Q2 Loss Per Share $0.19

* BD ANNOUNCES RESULTS FOR 2018 SECOND FISCAL QUARTER; RAISES FISCAL 2018 GUIDANCE

BRIEF-Becton Dickinson Files For Potential Mixed Shelf Offering

* BECTON DICKINSON AND CO FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2HvryvV) Further company coverage:

BRIEF-Becton Dickinson Updates Instructions for Use for Certain BD Vacutainer Blood Collection Tubes

* BECAME AWARE OF CONCERNS ABOUT INACCURATE LEAD TEST RESULTS FROM MAGELLAN DIAGNOSTICS LEADCARE TESTING SYSTEMS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up